CD4 1 T-helper cells that selectively produce interleukin (IL)-17 (T H 17), are critical for host defence and autoimmunity [1] [2] [3] [4] . Although crucial for T H 17 cells in vivo 5, 6 , IL-23 has been thought to be incapable of driving initial differentiation. Rather, IL-6 and transforming growth factor (TGF)-b1 have been proposed to be the factors responsible for initiating specification [7] [8] [9] [10] . Here we show that T H 17 differentiation can occur in the absence of TGF-b signalling. Neither IL-6 nor IL-23 alone efficiently generated T H 17 cells; however, these cytokines in combination with IL-1b effectively induced IL-17 production in naive precursors, independently of TGF-b. Epigenetic modification of the Il17a, Il17f and Rorc promoters proceeded without TGF-b1, allowing the generation of cells that co-expressed RORct (encoded by Rorc) and T-bet. T-bet 1 RORct 1 T H 17 cells are generated in vivo during experimental allergic encephalomyelitis, and adoptively transferred T H 17 cells generated with IL-23 without TGF-b1 were pathogenic in this disease model. These data indicate an alternative mode for T H 17 differentiation. Consistent with genetic data linking IL23R with autoimmunity, our findings re-emphasize the importance of IL-23 and therefore may have therapeutic implications.
TGF-b1 is important for murine T H 17 differentiation 7, 8 and accordingly, transgenic expression of a mutant TGF-b subunit receptor II (CD4dnTGF-bRII) in T cells interferes with the generation of T H 17 cells in the setting of experimental allergic encephalomyelitis (EAE) 11 . We revisited this issue by assessing whether T H 17 cells were present in the intestinal lamina propria of these mice. As expected, increased proportions and absolute numbers of interferon (IFN)-c-producing CD4 1 T cells were present ( Supplementary Fig. 1a ). Of note, IL-17producing CD4 1 cells were also present; the proportions were reduced, but there were no differences in the absolute numbers between wildtype and CD4dnTGF-bRII mice (Fig. 1a ). We confirmed this finding using mice that lack the TGF-b receptor subunit I in their T cells (Tgfbr1 f/f CD4-Cre 1 mice) 12 (Fig. 1b ). Rorct-expressing CD4 1 lamina propria T cells were also present in Tgfbr1 f/f CD4-Cre 1 mice, whereas Foxp3 1 CD4 1 T cells were markedly reduced ( Fig. 1b ). Collectively, these data indicate that in vivo T H 17 differentiation can occur in the absence of TGF-b signalling.
We next explored whether it was possible to differentiate naive T H 17 cells in vitro in the absence of TGF-b. Sorted naive CD4 1 T cells cultured in serum-free medium with no exogenous cytokines failed to produce Il17a mRNA (Fig. 1c ). The combination of IL-6, IL-1b and TGF-b1 efficiently induced Il17a mRNA, whereas IL-6 in the absence of TGF-b1 or IL-1b failed to do so. IL-23 alone failed to induce Il17a mRNA, but the combination of IL-6, IL-1b and IL-23, without TGF-b, induced Il17a transcription ( Fig. 1c ) and protein expression ( Fig. 1d and Supplementary Fig. 1b ).
To exclude the possibility that endogenously produced TGF-b might contribute to T H 17 differentiation, we cultured cells in the presence of anti-TGF-b antibodies. These antibodies blocked T H 17 differentiation induced by a combination of TGF-b1, IL-6 and IL-1b (TGF-b1/IL-6/ IL-1b), and enhanced IL-2 production, but had no significant effect on T H 17 differentiation induced by IL-23/IL-6/IL-1b ( Fig. 1d, e ). Similar results were also obtained in the absence of IL-1b and in medium supplemented with serum ( Supplementary Fig. 1c, d ). Anti-TGF-b antibodies blocked Foxp3 expression and T H 17 differentiation over a wide concentration of exogenous TGF-b1, but had no effect on IL-23-dependent T H 17 differentiation ( Supplementary Fig. 2a ). TGFb-independent T H 17 differentiation by IL-23/IL-6/IL-1b was also confirmed using a TGF-b receptor serine kinase inhibitor (TGF-bRi) ( Supplementary Fig. 2b ), and T cells from CD4dnTGF-bRII and Tgfbr1 f/f CD4-Cre 1 mice ( Supplementary Fig. 2c, d ). IL-23/IL-6/IL-1b-induced expression of Il21 and Il22 was also unaffected by the TGF-bRi ( Supplementary Fig. 2e ). In fact, T H 17 cells generated with IL-23/IL-6/IL-1b showed enhanced IL-22 production compared to TGF-b/IL-6/IL-1b-induced T H 17 cells ( Supplementary Fig. 2f ). IL-17F expression was similar under both conditions. Absence of TGF-bR1 expression and disruption of TGF-b signalling in Tgfbr1 f/f CD4-Cre 1 T cells or in T cells treated with the TGF-bRi were confirmed by the absence of SMAD2 phosphorylation and gene induction by TGF-b1 (Supplementary Figs 2g, h and 3a, b).
If our model is correct, an essential aspect of T H 17 differentiation is the induction of IL-23R independently of TGF-b. We found that IL-6 and IL-1b induced Il23r mRNA expression in the absence of TGF-b. Addition of IL-23 significantly increased expression, whereas TGF-b1 inhibited expression ( Fig. 2a, b and Supplementary Fig. 3c ). Accordingly, the IL-23-mediated induction of the T H 17 phenotype was altered by TGF-b1 ( Supplementary Fig. 3d ). The inhibitory effect of TGF-b signalling on Il23r expression was also evident using the TGF-bRi and in cells with impaired TGF-b signalling ( Supplementary Fig. 3e , f). Because IL-23 and IL-6 exert their effects through STAT3, we also documented that STAT3 binds the Il23r locus using chromatin immunoprecipitation with massive parallel sequencing ( Fig. 2c ).
We next determined whether acquisition of permissive epigenetic modifications and extinction of repressive modifications of the Il17a/ Il17f and Rorc loci also occurred in the absence of TGF-b. In serumfree media, we found that in the presence of IL-6 and IL-1b, TGF-b or IL-23 were effective in inducing histone 3 lysine 4 trimethylation (H3K4me3) of the Il17a and Il17f promoters ( Fig. 2d ). Recruitment of the transcriptional co-activator p300 also occurred in response to both factors, whereas stimulation with IL-6 and IL-1b alone resulted in loss of the repressive mark, histone 3 lysine 9 trimethylation (H3K9me3). Although TGF-b1 seemed to be a more efficient inducer 
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of Rorc, p300 was recruited to this locus in response to IL-23, and RORct protein induction was detected in the absence of TGF-b1 ( Fig. 2d and Supplementary Fig. 3g ).
To compare IL-23/IL-6-induced T H 17 (T H 17 (23)) cells with conventional T H 17 cells (T H 17(b)), we assessed global gene expression in both cells and found more than 2,000 genes differentially expressed ( Supplementary Fig. 4a, b ). As shown in Fig. 3a , conventional T H 17(b) cells expressed higher levels of Il9, Il10 and Ccl20, whereas T H 17 (23) cells expressed higher levels of Il2, Il33 and Il18r1. These differences were confirmed by quantitative PCR and measurement of protein expression ( Fig. 3b and Supplementary Fig. 4c-e ). To assess whether IL-17-producing cells with a phenotype similar to those induced in vitro in the absence of TGF-b are generated in vivo, mice were immunized with ovalbumin and adjuvant. By day 7 most IL-17-producing OT-II CD4 1 T cells also expressed IL-18R1 and produced IL-2 (ref. 6) (Supplementary Fig. 4f ). Collectively, these data support the in vivo relevance of TGF-b-independent generation of T H 17 cells.
Conventional T H 17(b) and IL-23-induced T H 17(23) cells both expressed Rorc. As expected, T H 17(b) cells expressed Maf and Ahr mRNA. In contrast, T H 17(23) cells expressed Tbx21 and Hlx mRNA ( Fig. 3c and Supplementary Fig. 5a, b) and T-bet protein (Figs 3d, e ). In the absence of T-bet, the proportion of IL-17-producing cells induced by IL-23/IL-6/IL-1b was increased (Fig. 3f ). Having demonstrated that T H 17(23) cells retained T-bet expression, we wondered how this would influence cytokine production. As shown in Supplementary Fig. 6a , IL-23/IL-6/IL-1b induced slightly fewer IL-17-producing cells than the conventional pathway using TGF-b1. Expansion of cells in IL-2 and TGF-b1 resulted in reduction in IL-17 expression in both subsets. T H 17 cells cultured in IL-12 acquired the ability to make IFN-c 13 ; however, this was significantly enhanced in T H 17(23) cells (Supplementary Fig. 6b ). Previous studies have suggested that a major function of TGF-b is to downregulate T-bet and to prevent T H 17 cells from acquiring the capacity to produce IFN-c 13, 14 . We therefore performed transcriptional profiling on conventional T H 17 cells cultured with TGF-b1 and IL-6 in the presence and absence of the TGF-bRi. In addition to contributing to the changes observed in cytokines and chemokines ( Supplementary Fig. 5c ), we found that blocking TGF-b1 resulted in the upregulation of Tbx21 and Gata3 mRNA (Supplementary Fig. 5a, d) .
It is well established that IL-23 is critical for the development of EAE, but T-bet is also critical, a finding that does not fit well with our current understanding of T H 17 cell development 15 . The present findings indicate that T H 17 cells, which arise in the absence of TGF-b, would express RORct and T-bet. To test if such cells are seen in vivo, we immunized Rorc(ct)-Gfp TG -reporter mice 16 with myelin oligodendrocyte glycoprotein (MOG)35-55 peptide. We found that approximately 25-60% of RORct 1 IL-17 1 CD4 1 cells in the CNS expressed T-bet ( Fig. 4a, b ). Furthermore, a significantly higher proportion of the RORct, T-bet double-positive T H 17 cell population is found within the CNS compared with RORct single-positive T H 17 cells (Fig. 4b) .
To investigate the pathogenic potential of both subsets of T H 17 cells, we isolated naive T cells from TCR transgeneic (2D2) mice that recognize MOG35-55 peptide and differentiated them into T H 17(23) cells in the presence of anti-TGF-b antibodies or alternatively into conventional T H 17(b) cells resulting in a higher percentage of IL-17-producing cells (Fig. 4c ). After adoptive transfer, T H 17(23) cells provoked significantly more severe disease than that induced by T H 17(b) cells (Fig. 4d ). This was associated with significantly greater total numbers of IL-17 1 and IFN-c 1 T cells within the CNS (Fig. 4e, f) and elevated numbers of double-producer T cells ( Supplementary Fig. 6c ). In contrast, T H 17(b) cells were poorly pathogenic after adoptive transfer 17 , and preferentially trafficked to the spleen ( Supplementary Fig. 6d ).
Although initial reports suggested that IL-23 was a driver of IL-17 production 2,18-20 , the lack of IL-23R on naive CD4 1 T cells has been a factor in demoting this cytokine from an inducer of T H 17 differentiation to a restricted role in T H 17 expansion or preservation of pathogenicity 6, 21 . In its place, TGF-b1 has been proposed to be the primary inductive factor that specifies T H 17 differentiation in conjunction with IL-6. The current data indicate that TGF-b is not always necessary. IL-6 acting via STAT3 induces Il23r transcription, and IL-23 further enhances its own receptor expression. These cytokines in conjunction with IL-1b are sufficient to induce transcription and epigenetic modification of the Il17a/Il17f and Rorc loci, independently of TGF-b1. These data thus shed light on previous contradictory data pertaining to mouse versus human T H 17 differentiation and indicate that there may be no species-specific difference [22] [23] [24] .
The present data do not dispute the idea that TGF-b1 and IL-6 induce T H 17 differentiation ( Supplementary Fig. 7) . TGF-b is ubiquitous and undoubtedly is present at sites of inflammation. However, it is clear that TGF-b1 inhibits T-bet expression 13, 14 . Although this stabilizes the phenotype of selective IL-17 production, the T H 17 cells generated in the presence of TGF-b1 and IL-6 are not pathogenic in the model tested and produce IL-9 and IL-10 (refs 16, 17, 21, 25, 26 ). By contrast, T H 17 cells derived in the presence of IL-23 seem to have greater pathogenic potential. They express T-bet and IL-18R1, which each are essential for 
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the development of EAE 15, 17, 27 , and express CXCR3, which is important for trafficking of T cells to sites of inflammation 28, 29 . In addition, TGF-b1 suppresses IL-23R expression and IL-23-mediated IL-22 production. The diversity of IL-17-producing cells helps to resolve previously perplexing data in EAE, namely the limited pathogenicity of T H 17 cells generated with TGF-b and the importance of STAT3, IL-23R 5,6 , T-bet 15, 17 and IL-18R1 27 . The expression of characteristic 'Th1' markers by T H 17 (23) cells underscores the complexity of T-helper cell lineage specification. Importantly, T-bet 1 RORct 1 T H 17 cells are present in lesional tissue in EAE, but also from patients with multiple sclerosis 30 . Thus, T H 17 cells may represent heterogeneous populations comprising the offspring of T H 17(b) or T H 17(23) cells with distinct trafficking profiles and differing abilities to provoke autoimmune disease. These data are also of interest given the genetic link between IL23R polymorphisms and susceptibility to human autoimmune diseases. Future therapies for autoimmune disease should consider the phenotypic characters of pathogenic T H 17 cells, generated in the absence of TGF-b, and their signalling pathways as possible targets.
METHODS SUMMARY
Mice. C57BL/6J, B6.Cg-Tg(Cd4-TGFBR2)16Flv/J (CD4dnTGF-bRII), C57BL/ 6-Tg(Tcra2D2,Tcrb2D2)1Kuch/J (TCR(2D2)) and B6.129S6-Tbx21 tm1Glm /J (T-bet 2/2 ) mice were purchased from Jackson Laboratory, B6.129S6-Rag2 tm1Fwa (Rag2) mice from Taconic, Tgfbr1 f/f mice were bred with CD4-Cre 1 transgenic mice, and Tgfbr1 f/1 CD4-Cre 1 littermates were used as controls. OT-II CD45.1 1 mice, BAC-transgenic Rorc(ct)-Gfp TG mice and Rorc(ct)-Gfp TG2 littermate controls were previously described 6, 16 . All animal studies were performed according to the NIH guidelines for the use and care of live animals and were approved by the Institutional Animal Care and Use Committee of NIAMS or the IACUC of Schering-Plough Biopharma in accordance with guidelines of the Association for Assessment and Accreditation of Laboratory Animal Care. T-cell isolation and differentiation. CD4 1 T cells from spleens and lymph nodes of 6-8-week-old mice were purified by negative selection and magnetic separation (Miltenyi Biotec) followed by sorting of naive CD4 1 CD62L 1 CD44 2 CD25 2 population using FACSAria II (BD Biosciences). Cells were activated by platebound anti-CD3/CD28 (both 10 mg ml 21 ; eBioscience) in serum-free medium for 3-4 days either under neutral conditions or with IL-6 plus IL-1b (each 20 ng ml 21 ) and either human TGF-b1 (0.5 ng ml 21 ; T H 17(b)) or IL-23 (50 ng ml 21 ; T H 17(23)) (all from R&D Systems). In all cell cultures anti-IFN-c neutralizing antibodies (10 mg ml 21 , BD Pharmingen) were added. IL-12 (PeproTech) was used at 20 ng ml 21 , huIL-2 at 100 U ml 21 . Procedures for antagonizing TGF-b-signalling, isolation of lamina propria lymphocytes and CNS-infiltrating lymphocytes are given in Methods. The lower panel shows isotype control staining for T-bet and fluorescence in transgene-negative littermates. A representative staining is shown in a and pooled data of RORct 1 T-bet 2 and RORct 1 T-bet 1 IL-17 1 CD4 1 T cells are shown in b (n 5 7, *P , 0.05). c, Naive CD4 1 Vb11 1 CD62L 1 CD44 2 cells were isolated by cell sorting from TCR(2D2) transgenic mice. The cells were activated with anti-CD3/anti-CD28, IL-6, IL-1b and anti-IFN-c neutralizing antibodies with either TGF-b1 or IL-23 with anti-TGF-b neutralizing antibodies. The resultant cells were analysed for IL-17 and IL-10 expression by intracellular staining and flow cytometry. d, Polarized cells (1 3 10 6 ) were adoptively transferred into Rag2 2/2 recipients and mice were followed for signs of neurological disease. Data show mean 6 s.e.m. of the EAE clinical score of 20 mice pooled from two independent experiments. e, f, CNS-infiltrating mononuclear cells were isolated and the total number of CD4 1 T cells was determined in both groups (*P , 0.01, e). The absolute numbers of CNSinfiltrating IL-17 1 or IFN-c 1 CD4 1 T cells of each group were assessed by intracellular cytokine staining (*P , 0.05, **P , 0.01, f).
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